|
|
 |
|
Viewing report
|
|
|
|
Strategies for Building Biologics Capabilities and Franchises
Decision Resources, Inc., July 2010, Pages: 40
Hoping to face down patent cliffs and dwindling pipelines, pharmaceutical companies are aggressively entering the biologics arena. Building a new biologics business solely through organic growth is too slow, difficult, and expensive to be practical; therefore, companies are relying on M&As and corporate partnerships to do so. The changing face of the biologics market sector will bring more competition for traditional biologics innovator companies.
Questions answered in this report:
- The biologics sector offers Big Pharma potentially lucrative commercial opportunities. How large is this market? How do different classes of biological products contribute to the market? What growth in the biologics market is anticipated?
- The primary mode of entry into the biologics market has been through mergers and acquisitions (M&A). What M&A deals will have a significant impact on the biologics marketplace? What types of assets have pharmaceutical companies acquired? What successes have these deals yielded?
- Big Pharma can access biologics capabilities and pipelines through corporate partnerships with biotech companies. What is the focus of recent partnering activity? What assets do these deals bring to the pharmaceutical industry?
- Pharmaceutical companies are pursuing a variety of strategies to incorporate biologics into their portfolios or build up existing franchises. Which companies are developing innovative, branded biologics? Which companies are building capabilities to compete in biosimilars? How will these developments affect the biotech industry? What role can contract manufacturing organizations play?
Scope of the report:
Strategies for competing in biologics: M&As, corporate partnerships, branded strategies, biosimilars, healthcare reform bill, biosimilars regulatory pathways.
Abbott Laboratories: Case study, M&As, corporate partnerships, Knoll Pharmaceuticals, Solvay.
AstraZeneca: Case study, M&As, corporate partnerships, Cambridge Antibody Technology, MedImmune.
Bayer: Case study, M&As, corporate partnerships, Schering AG, Regeneron.
Bristol-Myers Squibb: Case study, M&As, corporate partnerships, ImClone Systems, Medarex, Adnexus Therapeutics.
Eli Lilly: Case study, M&As, corporate partnerships, early entry, ImClone Systems, Applied Molecular Evolution.
GlaxoSmithKline: Case study, M&As, corporate partnerships, vaccines, Human Genome Sciences, Amgen, GenMab, Domantis.
Johnson & Johnson: Case study, M&As, corporate partnerships, Centocor, Crucell, Elan.
Merck & Co.: Case study, M&As, corporate partnerships, Schering-Plough, combined biologics strategy, Merck BioVentures, GlycoFi, Insmed, Sirna.
Merck KGaA: Case study, M&As, corporate partnerships, Merck Serono, Serono.
Novartis: Case study, M&As, corporate partnerships, Chiron, vaccines, Novartis Biologics, Human Genome Sciences, Lonza, Sandoz.
Pfizer: Case study, M&As, corporate partnerships, Wyeth, Human Genome Sciences, Amgen, GenMab, Domantis.
Roche: Case study, M&As, corporate partnerships, Genentech, Bioinvent, Thrombogenics, Seattle Genetics, Alnylam Pharmaceuticals.
Sanofi-Aventis: Case study, M&As, corporate partnerships, Sanofi-Pasteur, vaccines, Regeneron Pharmaceuticals, Micromet, Merrimack Pharmaceuticals.
Teva: Case study, M&As, corporate partnerships, Barr Pharmaceuticals, CoGenesys, Lonza.
Outlook for biologics: Big Pharma threats, M&A and partnering successes, contract manufacturing organizations, competition with biotech innovators.
Market forecast: Biologics market forecast from Decision Resources’ Pharmaview
Customers who bought this item also bought
Biotech Investment and Business Trends: Weathering the Economic Storm
Biotech Investment and Business Trends: Surviving the Long Road to Market
Are Biologics the Wave of the Future?
Riding the Biotech Economic Tsunami - Surfing to Safety or Wipeout?
Success with Biobetters: Young Biobetters Companies and Pipelines
Antibody Technology Companies 2010
Biologics Pipelines: Who Has the Next Promising Recombinant Proteins?
Evolving Trends in Licensing: Strategies for Building and Retaining Value in Biotechnology Alliances
Top 50 Biotechnology Companies & Their Pipelines 2010
Key Issues to Consider When Bringing Biologics to Market in Europe and Japan
|
|
|
|
